Renhe Pharmacy Co Ltd

Renhe Pharmacy released its 2026 interim report. During the reporting period, the company's total operating revenue was 2.091 billion yuan, and net profit attributable to the parent company was 292 million yuan. Net cash inflow from operating activities was 572 million yuan, a decrease of 99.0157 million yuan compared with the same period last year, down 14.75 percent year on year. The company's latest asset-liability ratio was 11.85 percent, and gross margin was 35.96 percent, ranking 35th among peer companies that have already disclosed results. Diluted earnings per share were 0.21 yuan, total asset turnover was 0.26 times, and inventory turnover was 3.17 times. The number of shareholders was 88,600, and the top ten shareholders held 34.09 percent of total share capital.

Renhe Pharmacy announced that its share buyback plan through centralized competitive bidding has been fully implemented. A total of 17.7 million shares were repurchased, accounting for 1.2643 percent of the company's total share capital, with a total transaction amount of approximately 99.9996 million yuan. The buyback was carried out between April 28, 2026 and August 5, 2026, with the highest transaction price at 5.73 yuan per share and the lowest at 4.86 yuan per share. The company had previously planned to use its own funds of 80 million to 150 million yuan to repurchase shares for future equity incentives or employee stock ownership plans, with a buyback price not exceeding 8.00 yuan per share. The repurchased shares are temporarily held in the company's dedicated buyback securities account. If not fully granted within 36 months after the completion of the buyback, the ungranted shares will be fully cancelled.